A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
At least two groups have posted early data on T-cell tests for Covid-19; now Qiagen has licensed tech to make its own.
Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.
The effort has implications for international travel and allocating vaccines – but the precise quantitative tests necessary for this do not, as yet, exist.
Merck's move on a target that has attracted little attention – Liv-1 – means future data readouts are now eagerly awaited.
Licensing deal could enable bundling of antipsychotics with management technology.
Abbvie signs up China’s I-Mab instead of Trillium, but several other early-stage contenders are looking at the novel immuno-oncology mechanism.